HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NEUP
Neuphoria Therapeutics Inc.
There isn't enough reported data to score NEUP yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NEUP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
NEUP's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NEUP PE Valuation
NEUP has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NEUP Forward outlook
There aren't enough analyst estimates for NEUP to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NEUP Earnings Per Share
NEUP and HIMS do not have enough comparable growth data to identify a winner.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
NEUP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $45.5K | -22% |
| Q3 2022 | $45.5K | -21% |
| Q2 2022 | $2M | +1720% |
| Q1 2022 | $2M | +1722% |
| Q4 2021 | $58K | -72% |
| Q3 2021 | $57.9K | -72% |
| Q2 2021 | $110.6K | -75% |
| Q1 2021 | $110.5K | -75% |
NEUP's revenue is shrinking: $15M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | 80% | N/A |
| Q4 2024 | -559% | N/A |
| Q4 2022 | -19265% | -8315 points |
| Q3 2022 | -3529% | +7420 points |
| Q2 2022 | -256% | +2831 points |
| Q1 2022 | -422% | +2665 points |
| Q4 2021 | -10950% | -9913 points |
| Q3 2021 | -10950% | -9913 points |
NEUP's operating margin was 80% last quarter, up 336 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
NEUP has the stronger cash trend. Its trailing FCF is down 54% versus its history, compared with HIMS at down 84%.
NEUP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$3.3M | -129% |
| Q4 2025 | -$6.4M | -$3.1M |
| Q3 2025 | -$3.8M | +$638.4K |
| Q1 2025 | $11.5M | +$14.9M |
| Q4 2024 | -$3.4M | +$599.7K |
| Q3 2024 | -$4.4M | +$303.1K |
| Q1 2024 | -$3.5M | +$177.8K |
| Q4 2023 | -$4M | -$874.2K |
NEUP has burned cash in almost every quarter: −$12M over the past year, against $188,683 the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NEUP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NEUP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -19% | -1M shares |
| 1 year | +156% | +2.7M shares |
NEUP has 4M diluted shares, up 156% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | $554,738 |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NEUP Net Leverage
NEUP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NEUP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.3 | Neutral |
| Stochastic | 2.8 | Oversold |
NEUP's weekly RSI is 30 (neutral) and its Stochastic is 3 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NEUP PE vs Healthcare Sector
NEUP has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
NEUP has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus NEUP above 0 of 4.
NEUP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.20 | 19% below |
| 20 week MA | $3.50 | 26% below |
| 50 week MA | $4.07 | 37% below |
| 100 week MA | $5.48 | 53% below |
NEUP is in a downtrend: it's below all four of its weekly moving averages, and 53% below its 100-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NEUP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $2.91 | $4.03 | +38% |
| 2025 | $4.03 | $3.72 | -7.7% |
| 2026 YTD | $3.72 | $2.58 | -31% |
NEUP has the edge over HIMS on returns for 2026, with the stronger performance.